Vitestro, an Utrecht, The Netherlands-based autonomous blood drawing company, raised $22M in funding.
The round was led by Sonder Capital and new investor NYBC Ventures, with participation from Invest-NL, the European Innovation Council Fund (EIC Fund), and existing private investors. This brought its total funding raised to $50M (€46M) from both equity investments and grant funding.
The company intends to use the funds to expand the team to meet the demand for its robotic blood drawing device and develop additional product features.
Founded in 2017 and led by CEO Toon Overbeeke, and Brian Joseph, commercial director, Vitestro is committed to improving the blood draw experience for patients and clinicians via its autonomous technology and a team of more than 70 specialists in medical robotics, artificial intelligence, imaging software, and healthcare commercialization.
Through a combination of artificial intelligence (AI), advanced imaging technology, and robotics, the company’s system enables hospitals and labs to provide accurate and autonomous blood draws, reducing the need for manual handling and improving patient and clinician satisfaction. Multiple Vitestro devices have already been pre-ordered and are scheduled to be deployed at several European hospitals starting at the end of this year. The company is also currently leading the A.D.O.P.T. trial, a large evaluation of its autonomous blood drawing devices. and is on track to obtain CE approval for its device by the end of 2024.
FinSMEs
30/04/2024